Yu Jia, Liao Pei-Ju, Keller Thomas H, Cherian Joseph, Virshup David M, Xu Weijun
Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
Experimental Drug Development Centre, 10 Biopolis Road, Chromos, Singapore 138670, Singapore.
iScience. 2024 Jul 5;27(8):110454. doi: 10.1016/j.isci.2024.110454. eCollection 2024 Aug 16.
Wnts are lipid-modified glycoproteins that play key roles in both embryonic development and adult homeostasis. Wnt signaling is dysregulated in many cancers and preclinical data shows that targeting Wnt biosynthesis and secretion can be effective in Wnt-addicted cancers. An integral membrane protein known as Wntless (WLS/Evi) is essential for Wnt secretion. However, WLS remains undrugged thus far. The cryo-EM structure of WLS in complex with WNT8A shows that WLS has a druggable G-protein coupled receptor (GPCR) domain. Using Active Learning/Glide, we performed an ultra-large scale virtual screening from Enamine's REAL 350/3 Lead-Like library containing nearly 500 million compounds. 68 hits were examined after on-demand synthesis in cell-based Wnt reporter and other functional assays. ETC-451 emerged as a potential first-in-class WLS inhibitor. ETC-451 blocked WLS-WNT3A interaction and decreased Wnt-addicted pancreatic cancer cell line proliferation. The current hit provides a starting chemical scaffold for further structure or ligand-based drug discovery targeting WLS.
Wnt 是脂质修饰的糖蛋白,在胚胎发育和成人稳态中均发挥关键作用。Wnt 信号传导在许多癌症中失调,临床前数据表明,靶向 Wnt 生物合成和分泌对依赖 Wnt 的癌症可能有效。一种名为无翅型MMTV整合位点家族成员(Wntless,WLS/Evi)的整合膜蛋白对Wnt分泌至关重要。然而,到目前为止WLS仍未成为药物作用靶点。WLS与WNT8A复合物的冷冻电镜结构表明,WLS具有一个可成药的G蛋白偶联受体(GPCR)结构域。我们使用主动学习/Glide程序,对包含近5亿种化合物的Enamine公司REAL 350/3类先导化合物库进行了超大规模虚拟筛选。在基于细胞的Wnt报告基因及其他功能试验中按需合成后,对68个命中化合物进行了检测。ETC-451成为一种潜在的一流WLS抑制剂。ETC-451阻断了WLS与WNT3A的相互作用,并降低了依赖Wnt的胰腺癌细胞系的增殖。当前的命中化合物为进一步针对WLS进行基于结构或配体的药物发现提供了起始化学支架。